Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement
In patients with aortic valve stenosis (AS), cardiac sympathetic nervous (CSN) dysfunction and its improvement after transcatheter aortic valve replacement (TAVR) have been reported. The prognostic impact of CSN function remains unclear. This study investigated the prognostic value of cardiac I-meta...
Gespeichert in:
| Veröffentlicht in: | ESC Heart Failure 2021-04, Vol.8 (2), p.1106-1116 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1116 |
|---|---|
| container_issue | 2 |
| container_start_page | 1106 |
| container_title | ESC Heart Failure |
| container_volume | 8 |
| creator | Kadoya, Yoshito Zen, Kan Tamaki, Nagara Yashige, Masaki Takamatsu, Kazuaki Ito, Nobuyasu Kuwabara, Kensuke Yamano, Michiyo Yamano, Tetsuhiro Nakamura, Takeshi Yaku, Hitoshi Matoba, Satoaki |
| description | In patients with aortic valve stenosis (AS), cardiac sympathetic nervous (CSN) dysfunction and its improvement after transcatheter aortic valve replacement (TAVR) have been reported. The prognostic impact of CSN function remains unclear. This study investigated the prognostic value of cardiac
I-metaiodobenzylguanidine (MIBG) imaging for predicting cardiac events after TAVR.
This single-centre prospective observational study enrolled patients with AS between July 2017 and May 2019. MIBG scintigraphy was performed before and soon after TAVR to evaluate the late heart-mediastinum ratio (L-H/M). Patients were classified into three pairs of groups based on the baseline and post-TAVR L-H/M (≥2.0 or |
| doi_str_mv | 10.1002/ehf2.13123 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475398305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475398305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1963-c5108683f3e089727a832125665bc234f3faf5d7606a65f2fee91d44d7e00e013</originalsourceid><addsrcrecordid>eNpdkc9KxDAQxoMoKroXH0ACXkSoTpImbY8i_gNBD3ou2XSyRtpkTdqF9Rl8aLvuKuJp5oPffDPMR8gRg3MGwC_w1fJzJhgXW2Sfg5SZLDnf_tPvkUlKbwDApGKS57tkT4gcQFRsn3w-xTDzIfXO0IVuB6TBUqNj47Shoym9zzrstQtNmKL_WLazQXvXOI_UdXrm_IzaEOk8YuNMv5I_w7hA3yeqbY-R9lH7ZHT_iiulQ9zsWyCNOG-1wW6kD8mO1W3CyaYekJeb6-eru-zh8fb-6vIhM6xSIjOSQalKYQVCWRW80KXgjEul5NRwkVthtZVNoUBpJS23iBVr8rwpEACBiQNyuvadx_A-YOrrziWDbas9hiHVPC-kqEoBckRP_qFvYYh-vK7mEhTPVVGUI3W2pkwMKUW09TyO74nLmkG9iqlexVR_xzTCxxvLYdph84v-hCK-ACKAjes</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506246778</pqid></control><display><type>article</type><title>Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Kadoya, Yoshito ; Zen, Kan ; Tamaki, Nagara ; Yashige, Masaki ; Takamatsu, Kazuaki ; Ito, Nobuyasu ; Kuwabara, Kensuke ; Yamano, Michiyo ; Yamano, Tetsuhiro ; Nakamura, Takeshi ; Yaku, Hitoshi ; Matoba, Satoaki</creator><creatorcontrib>Kadoya, Yoshito ; Zen, Kan ; Tamaki, Nagara ; Yashige, Masaki ; Takamatsu, Kazuaki ; Ito, Nobuyasu ; Kuwabara, Kensuke ; Yamano, Michiyo ; Yamano, Tetsuhiro ; Nakamura, Takeshi ; Yaku, Hitoshi ; Matoba, Satoaki</creatorcontrib><description>In patients with aortic valve stenosis (AS), cardiac sympathetic nervous (CSN) dysfunction and its improvement after transcatheter aortic valve replacement (TAVR) have been reported. The prognostic impact of CSN function remains unclear. This study investigated the prognostic value of cardiac
I-metaiodobenzylguanidine (MIBG) imaging for predicting cardiac events after TAVR.
This single-centre prospective observational study enrolled patients with AS between July 2017 and May 2019. MIBG scintigraphy was performed before and soon after TAVR to evaluate the late heart-mediastinum ratio (L-H/M). Patients were classified into three pairs of groups based on the baseline and post-TAVR L-H/M (≥2.0 or <2.0) and on the presence of TAVR-related improvement in L-H/M. The study endpoint was the occurrence of major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction, and hospitalization due to heart failure. Among the 187 consecutive patients who underwent TAVR, 107 (27 men; median age: 86 years) were evaluated. Over a median follow-up of 366 days, 15 (14.0%) patients had MACE. The incidence of MACE was significantly low in patients with L-H/M improvement and/or high post-TAVR L-H/M (≥2.0). Baseline L-H/M and frailty were associated with poor response of L-H/M to TAVR treatment. TAVR-related improvement in L-H/M had significant effects on MACE, with an adjusted hazard ratio of 0.233 (95% confidence interval, 0.064-0.856; P = 0.028).
TAVR-related improvement in L-H/M was an independent predictor of cardiac events, 1 year after TAVR. Cardiac MIBG imaging is useful for predicting cardiac events after TAVR.</description><identifier>ISSN: 2055-5822</identifier><identifier>EISSN: 2055-5822</identifier><identifier>DOI: 10.1002/ehf2.13123</identifier><identifier>PMID: 33400391</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Anesthesia ; Heart ; Hospitalization ; Hypotheses ; Hypothesis testing ; Medical prognosis ; Patients ; Scintigraphy ; Software</subject><ispartof>ESC Heart Failure, 2021-04, Vol.8 (2), p.1106-1116</ispartof><rights>2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1963-c5108683f3e089727a832125665bc234f3faf5d7606a65f2fee91d44d7e00e013</citedby><cites>FETCH-LOGICAL-c1963-c5108683f3e089727a832125665bc234f3faf5d7606a65f2fee91d44d7e00e013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33400391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kadoya, Yoshito</creatorcontrib><creatorcontrib>Zen, Kan</creatorcontrib><creatorcontrib>Tamaki, Nagara</creatorcontrib><creatorcontrib>Yashige, Masaki</creatorcontrib><creatorcontrib>Takamatsu, Kazuaki</creatorcontrib><creatorcontrib>Ito, Nobuyasu</creatorcontrib><creatorcontrib>Kuwabara, Kensuke</creatorcontrib><creatorcontrib>Yamano, Michiyo</creatorcontrib><creatorcontrib>Yamano, Tetsuhiro</creatorcontrib><creatorcontrib>Nakamura, Takeshi</creatorcontrib><creatorcontrib>Yaku, Hitoshi</creatorcontrib><creatorcontrib>Matoba, Satoaki</creatorcontrib><title>Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement</title><title>ESC Heart Failure</title><addtitle>ESC Heart Fail</addtitle><description>In patients with aortic valve stenosis (AS), cardiac sympathetic nervous (CSN) dysfunction and its improvement after transcatheter aortic valve replacement (TAVR) have been reported. The prognostic impact of CSN function remains unclear. This study investigated the prognostic value of cardiac
I-metaiodobenzylguanidine (MIBG) imaging for predicting cardiac events after TAVR.
This single-centre prospective observational study enrolled patients with AS between July 2017 and May 2019. MIBG scintigraphy was performed before and soon after TAVR to evaluate the late heart-mediastinum ratio (L-H/M). Patients were classified into three pairs of groups based on the baseline and post-TAVR L-H/M (≥2.0 or <2.0) and on the presence of TAVR-related improvement in L-H/M. The study endpoint was the occurrence of major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction, and hospitalization due to heart failure. Among the 187 consecutive patients who underwent TAVR, 107 (27 men; median age: 86 years) were evaluated. Over a median follow-up of 366 days, 15 (14.0%) patients had MACE. The incidence of MACE was significantly low in patients with L-H/M improvement and/or high post-TAVR L-H/M (≥2.0). Baseline L-H/M and frailty were associated with poor response of L-H/M to TAVR treatment. TAVR-related improvement in L-H/M had significant effects on MACE, with an adjusted hazard ratio of 0.233 (95% confidence interval, 0.064-0.856; P = 0.028).
TAVR-related improvement in L-H/M was an independent predictor of cardiac events, 1 year after TAVR. Cardiac MIBG imaging is useful for predicting cardiac events after TAVR.</description><subject>Anesthesia</subject><subject>Heart</subject><subject>Hospitalization</subject><subject>Hypotheses</subject><subject>Hypothesis testing</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Scintigraphy</subject><subject>Software</subject><issn>2055-5822</issn><issn>2055-5822</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc9KxDAQxoMoKroXH0ACXkSoTpImbY8i_gNBD3ou2XSyRtpkTdqF9Rl8aLvuKuJp5oPffDPMR8gRg3MGwC_w1fJzJhgXW2Sfg5SZLDnf_tPvkUlKbwDApGKS57tkT4gcQFRsn3w-xTDzIfXO0IVuB6TBUqNj47Shoym9zzrstQtNmKL_WLazQXvXOI_UdXrm_IzaEOk8YuNMv5I_w7hA3yeqbY-R9lH7ZHT_iiulQ9zsWyCNOG-1wW6kD8mO1W3CyaYekJeb6-eru-zh8fb-6vIhM6xSIjOSQalKYQVCWRW80KXgjEul5NRwkVthtZVNoUBpJS23iBVr8rwpEACBiQNyuvadx_A-YOrrziWDbas9hiHVPC-kqEoBckRP_qFvYYh-vK7mEhTPVVGUI3W2pkwMKUW09TyO74nLmkG9iqlexVR_xzTCxxvLYdph84v-hCK-ACKAjes</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Kadoya, Yoshito</creator><creator>Zen, Kan</creator><creator>Tamaki, Nagara</creator><creator>Yashige, Masaki</creator><creator>Takamatsu, Kazuaki</creator><creator>Ito, Nobuyasu</creator><creator>Kuwabara, Kensuke</creator><creator>Yamano, Michiyo</creator><creator>Yamano, Tetsuhiro</creator><creator>Nakamura, Takeshi</creator><creator>Yaku, Hitoshi</creator><creator>Matoba, Satoaki</creator><general>John Wiley & Sons, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement</title><author>Kadoya, Yoshito ; Zen, Kan ; Tamaki, Nagara ; Yashige, Masaki ; Takamatsu, Kazuaki ; Ito, Nobuyasu ; Kuwabara, Kensuke ; Yamano, Michiyo ; Yamano, Tetsuhiro ; Nakamura, Takeshi ; Yaku, Hitoshi ; Matoba, Satoaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1963-c5108683f3e089727a832125665bc234f3faf5d7606a65f2fee91d44d7e00e013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anesthesia</topic><topic>Heart</topic><topic>Hospitalization</topic><topic>Hypotheses</topic><topic>Hypothesis testing</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Scintigraphy</topic><topic>Software</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kadoya, Yoshito</creatorcontrib><creatorcontrib>Zen, Kan</creatorcontrib><creatorcontrib>Tamaki, Nagara</creatorcontrib><creatorcontrib>Yashige, Masaki</creatorcontrib><creatorcontrib>Takamatsu, Kazuaki</creatorcontrib><creatorcontrib>Ito, Nobuyasu</creatorcontrib><creatorcontrib>Kuwabara, Kensuke</creatorcontrib><creatorcontrib>Yamano, Michiyo</creatorcontrib><creatorcontrib>Yamano, Tetsuhiro</creatorcontrib><creatorcontrib>Nakamura, Takeshi</creatorcontrib><creatorcontrib>Yaku, Hitoshi</creatorcontrib><creatorcontrib>Matoba, Satoaki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>ESC Heart Failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kadoya, Yoshito</au><au>Zen, Kan</au><au>Tamaki, Nagara</au><au>Yashige, Masaki</au><au>Takamatsu, Kazuaki</au><au>Ito, Nobuyasu</au><au>Kuwabara, Kensuke</au><au>Yamano, Michiyo</au><au>Yamano, Tetsuhiro</au><au>Nakamura, Takeshi</au><au>Yaku, Hitoshi</au><au>Matoba, Satoaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement</atitle><jtitle>ESC Heart Failure</jtitle><addtitle>ESC Heart Fail</addtitle><date>2021-04</date><risdate>2021</risdate><volume>8</volume><issue>2</issue><spage>1106</spage><epage>1116</epage><pages>1106-1116</pages><issn>2055-5822</issn><eissn>2055-5822</eissn><abstract>In patients with aortic valve stenosis (AS), cardiac sympathetic nervous (CSN) dysfunction and its improvement after transcatheter aortic valve replacement (TAVR) have been reported. The prognostic impact of CSN function remains unclear. This study investigated the prognostic value of cardiac
I-metaiodobenzylguanidine (MIBG) imaging for predicting cardiac events after TAVR.
This single-centre prospective observational study enrolled patients with AS between July 2017 and May 2019. MIBG scintigraphy was performed before and soon after TAVR to evaluate the late heart-mediastinum ratio (L-H/M). Patients were classified into three pairs of groups based on the baseline and post-TAVR L-H/M (≥2.0 or <2.0) and on the presence of TAVR-related improvement in L-H/M. The study endpoint was the occurrence of major adverse cardiac events (MACE), defined as a composite of all-cause death, non-fatal myocardial infarction, and hospitalization due to heart failure. Among the 187 consecutive patients who underwent TAVR, 107 (27 men; median age: 86 years) were evaluated. Over a median follow-up of 366 days, 15 (14.0%) patients had MACE. The incidence of MACE was significantly low in patients with L-H/M improvement and/or high post-TAVR L-H/M (≥2.0). Baseline L-H/M and frailty were associated with poor response of L-H/M to TAVR treatment. TAVR-related improvement in L-H/M had significant effects on MACE, with an adjusted hazard ratio of 0.233 (95% confidence interval, 0.064-0.856; P = 0.028).
TAVR-related improvement in L-H/M was an independent predictor of cardiac events, 1 year after TAVR. Cardiac MIBG imaging is useful for predicting cardiac events after TAVR.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>33400391</pmid><doi>10.1002/ehf2.13123</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2055-5822 |
| ispartof | ESC Heart Failure, 2021-04, Vol.8 (2), p.1106-1116 |
| issn | 2055-5822 2055-5822 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2475398305 |
| source | DOAJ Directory of Open Access Journals; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Anesthesia Heart Hospitalization Hypotheses Hypothesis testing Medical prognosis Patients Scintigraphy Software |
| title | Prognostic value of cardiac 123 I-metaiodobenzylguanidine imaging for predicting cardiac events after transcatheter aortic valve replacement |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A44%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20cardiac%20123%20I-metaiodobenzylguanidine%20imaging%20for%20predicting%20cardiac%20events%20after%20transcatheter%20aortic%20valve%20replacement&rft.jtitle=ESC%20Heart%20Failure&rft.au=Kadoya,%20Yoshito&rft.date=2021-04&rft.volume=8&rft.issue=2&rft.spage=1106&rft.epage=1116&rft.pages=1106-1116&rft.issn=2055-5822&rft.eissn=2055-5822&rft_id=info:doi/10.1002/ehf2.13123&rft_dat=%3Cproquest_cross%3E2475398305%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506246778&rft_id=info:pmid/33400391&rfr_iscdi=true |